VEGFA and endophthalmitis: Multiple randomized controlled clinical studies [22–24] have demonstrated that anti-VEGF treatment can improve vision in PDR patients without baseline macular oedema at 1, 2, and 5 years without increased endophthalmitis or cardiovascular events.